MaxCyte Inc

MXCT · NASDAQ

Research and Development in Biotechnology · US

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.

ESG Overview

Overall: BB (Medium)

E: BS: BBG: B

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $0.88 +0.06 (+7.63%)

Market Cap$87M

P/E Ratio—

EPS$—

52W High$2.93

52W Low$0.64

Beta1.49

Data from Finnhub · Updated Apr 30, 2026